JP2018515506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515506A5 JP2018515506A5 JP2017558372A JP2017558372A JP2018515506A5 JP 2018515506 A5 JP2018515506 A5 JP 2018515506A5 JP 2017558372 A JP2017558372 A JP 2017558372A JP 2017558372 A JP2017558372 A JP 2017558372A JP 2018515506 A5 JP2018515506 A5 JP 2018515506A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- disease
- disorder
- calcium
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 229960001157 acamprosate calcium Drugs 0.000 claims 2
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000004641 brain development Effects 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000030251 communication disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 230000013016 learning Effects 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 238000003892 spreading Methods 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229920001169 thermoplastic Polymers 0.000 claims 1
- 239000004416 thermosoftening plastic Substances 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103349A JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156842P | 2015-05-04 | 2015-05-04 | |
| US62/156,842 | 2015-05-04 | ||
| US201562260161P | 2015-11-25 | 2015-11-25 | |
| US62/260,161 | 2015-11-25 | ||
| PCT/US2016/030725 WO2016179252A1 (en) | 2015-05-04 | 2016-05-04 | Sprinkle formulations of acamprosate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103349A Division JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515506A JP2018515506A (ja) | 2018-06-14 |
| JP2018515506A5 true JP2018515506A5 (enExample) | 2019-06-06 |
| JP7026347B2 JP7026347B2 (ja) | 2022-02-28 |
Family
ID=57217823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558372A Active JP7026347B2 (ja) | 2015-05-04 | 2016-05-04 | アカンプロサートのスプリンクル製剤 |
| JP2021103349A Pending JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103349A Pending JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10709668B2 (enExample) |
| EP (1) | EP3291800A4 (enExample) |
| JP (2) | JP7026347B2 (enExample) |
| KR (1) | KR102790656B1 (enExample) |
| AU (1) | AU2016258624B2 (enExample) |
| HK (1) | HK1252003A1 (enExample) |
| IL (1) | IL255343B2 (enExample) |
| SG (1) | SG11201708393UA (enExample) |
| WO (1) | WO2016179252A1 (enExample) |
| ZA (1) | ZA201708037B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3259600B1 (en) | 2015-02-18 | 2024-07-24 | MirZyme Therapeutics Limited | Diagnostic assay and treatment for preeclampsia |
| IL255343B2 (en) | 2015-05-04 | 2024-10-01 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
| EP3331518A4 (en) * | 2015-08-04 | 2019-04-03 | Confluence Pharmaceuticals, LLC | COMBINATION THERAPY WITH ACAMPROSATE AND D-CYCLOSERIN |
| IL270654B2 (en) * | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
| EP3459528B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
| EP4213817A1 (en) * | 2020-09-21 | 2023-07-26 | Sun Pharmaceutical Industries Limited | Multi-particulate pharmaceutical composition of quetiapine |
| WO2023048065A1 (ja) | 2021-09-24 | 2023-03-30 | 住友ベークライト株式会社 | 脳波検出用電極、脳波測定装置及び脳波測定方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| CA2328197C (en) | 1998-04-14 | 2007-11-20 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| RU2375048C2 (ru) * | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| JP2010532331A (ja) | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| US9463172B2 (en) | 2009-02-12 | 2016-10-11 | Indiana University Research & Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| CA2850468C (en) * | 2010-09-28 | 2019-08-13 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| ES2665569T3 (es) | 2011-03-01 | 2018-04-26 | Pharnext | Tratamiento de la isquemia cerebral |
| MX2021000431A (es) * | 2011-03-23 | 2022-10-28 | Ironshore Pharmaceuticals & Dev Inc | Metodos y composiciones para el tratamiento de trastorno por deficit de atencion. |
| KR20130002292A (ko) | 2011-06-28 | 2013-01-07 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| CN105431144A (zh) | 2013-06-05 | 2016-03-23 | 思康脑侒股份有限公司 | 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合 |
| SG11201606275WA (en) | 2014-02-11 | 2016-08-30 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| IL255343B2 (en) | 2015-05-04 | 2024-10-01 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
-
2016
- 2016-05-04 IL IL255343A patent/IL255343B2/en unknown
- 2016-05-04 SG SG11201708393UA patent/SG11201708393UA/en unknown
- 2016-05-04 AU AU2016258624A patent/AU2016258624B2/en active Active
- 2016-05-04 US US15/569,937 patent/US10709668B2/en active Active
- 2016-05-04 WO PCT/US2016/030725 patent/WO2016179252A1/en not_active Ceased
- 2016-05-04 JP JP2017558372A patent/JP7026347B2/ja active Active
- 2016-05-04 KR KR1020177033137A patent/KR102790656B1/ko active Active
- 2016-05-04 EP EP16789996.2A patent/EP3291800A4/en active Pending
- 2016-05-04 HK HK18111332.4A patent/HK1252003A1/zh unknown
-
2017
- 2017-11-27 ZA ZA2017/08037A patent/ZA201708037B/en unknown
-
2021
- 2021-06-22 JP JP2021103349A patent/JP2021155434A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515506A5 (enExample) | ||
| JP2011063627A5 (enExample) | ||
| IL255782A (en) | Extended release pharmaceutical compositions of levetiracetam | |
| AU2020227021B2 (en) | Methods and compositions particularly for treatment of attention deficit disorder | |
| JP2020023518A5 (enExample) | ||
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| MX2021005106A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| EP3215147A1 (en) | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | |
| JP2018516906A5 (enExample) | ||
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| JP2017536407A5 (enExample) | ||
| NZ591873A (en) | Co-crystals of tramadol and nsaids | |
| JP2017019874A (ja) | アマンタジン組成物および使用方法 | |
| JP2017505811A5 (enExample) | ||
| JP2014516535A5 (enExample) | ||
| TW200738228A (en) | Neramexane modified release matrix tablet | |
| CN103845335A (zh) | 吉非替尼药物组合物及含有这一吉非替尼药物组合物的片剂 | |
| Zhang et al. | Research progress of preparation technology of ion-exchange resin complexes | |
| JP2018526345A5 (enExample) | ||
| WO2008120070A3 (en) | 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon | |
| JP2019513814A5 (enExample) | ||
| JP2014507475A5 (enExample) | ||
| CN106265601A (zh) | 一种布洛芬缓释制剂及其制备方法 | |
| CN101947209B (zh) | 双丙戊酸钠小丸及其制备方法 | |
| JP2019014666A5 (enExample) |